ReviewCureus2026
Autoimmune and Inflammatory Diseases Associated With Increased Periprosthetic Joint Infection Risk: A Narrative Review of Pathophysiology, Risk Stratification, and Perioperative Management.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periprosthetic joint infection (PJI) is a devastating complication of total joint arthroplasty. Patients with autoimmune and inflammatory diseases, psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) face substantially elevated infection risk through three convergent mechanisms: skin barrier dysfunction, systemic immune dysregulation, and the immunosuppressive therapies required to control their disease. This narrative review synthesizes evidence from cohort studies, registry analyses, mechanistic investigations, and clinical practice guidelines to examine PJI pathophysiology, comparative risk quantification, microbiologic profiles, and perioperative management strategies in this high-risk population. RA patients demonstrated hazard ratios of 4.08 (95% CI 1.35-12.33) and odds ratios of 1.47 (95% CI 1.13-1.91) for PJI compared with osteoarthritis controls; psoriasis patients showed an odds ratio of 1.63 (p = 0.014) for 90-day PJI after total shoulder arthroplasty; and SLE patients carried a hazard ratio of 2.74 (95% CI 1.14-6.64) for late PJI after total hip arthroplasty. These estimates derived from heterogeneous studies and were presented descriptively rather than as pooled values. Perioperative continuation of biologic therapy increased PJI odds by 3.46-fold (95% CI 1.11-10.78), and chronic glucocorticoid use exceeding 10 mg/day approximately doubled infection risk. The microbiologic profile was distinct, with culture-negative infection reported in roughly 28%-38% of cases in a single-center case series of RA patients and methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.